Many of these GLP-1 medications, including those developed by Eli Lilly, are supported by extensive clinical trials and real-world clinical study data
First, the evidence is limited to draw a definitive conclusion: only four small or moderate sized RCTs were included, and the risk of bias is generally moderate
Why Employers Are Zeroing In On GLP-1s The numbers tell the story: 40% of US adults are living with obesity, with projections closer to 50% by 2030 Employers spend $6,472 more per year on employees with obesity than on healthy-weight employees across medical, productivity, disability, and workers comp Individuals who use GLP-1s can lose between 2.5% and 20% of their initial body weight when taking the medication as instructed Employers want to support prevention, not wait until employees are sicker to qualify for care
Importantly, the presence of benzyl alcohol does not alter the essential physical properties of the water
Similarly, trauma induced increased Flavonifractor may potentially compromise GABA availability, since these bacteria primarily utilize GABA for metabolism (Tanelian et al., 2023) potentially affecting this key inhibitory neurotransmitter and contributing to anxiety symptoms observed in PTSD (Strandwitz et al., 2018)
Rapid weight loss from Mounjaro can change facial appearance, including facial volume and skin elasticity, which may impact the effectiveness and placement of Botox